ANTI-GLYCOPROTEIN IIb/IIIa ANTIBODIES

1 . An antibody or antigen-binding fragment thereof that specifically binds to Glycoprotein IIb/IIIa (GPIIb/IIIa), wherein the antibody or antigen-binding fragment thereof:

(i) preferentially binds to GPIIb/IIIa on activated platelets compared to resting platelets; and

(ii) does not activate platelets.

2 . The antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment thereof does not inhibit the association of fibrinogen with GPIIb/IIIa.

3 . The antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises:

(i) the complementarity determining regions (CDRs) of the heavy chain variable domain (VH) amino acid sequence set forth in SEQ ID NOs. 9, 29, 33, or 37;

(ii) an amino acid sequence that is at least 85% identical to the VH amino acid sequence set forth in SEQ ID NOs. 9, 29, 33, or 37;

(iii) the complementarity determining regions of the light chain variable domain (VL) amino acid sequence set forth in SEQ ID NOs. 11, 31, 35, or 39; or

(iv) an amino acid sequence that is at least 85% identical to the VL amino acid sequence set forth in SEQ ID NOs. 11, 31, 35, or 39.

4 .- 8 . (canceled)

9 . An antibody or antigen-binding fragment thereof that specifically binds to Glycoprotein IIb/IIIa (GPIIb/IIIa), wherein the antibody or antigen-binding fragment thereof:

(i) binds to GPIIb/IIIa on both activated platelets and resting platelets; and

(ii) does not activate platelets.

10 . The antibody or antigen-binding fragment thereof of claim 9 , wherein the antibody or antigen-binding fragment thereof comprises:

(i) the complementarity determining regions of VH amino acid sequence set forth in SEQ ID NOs. 5, 13, 17, 21, 25, 41, 45, or 49;

(ii) a VH amino acid sequence that is at least 85% identical to the amino acid sequence set forth in SEQ ID NOs. 5, 13, 17, 21, 25, 41, 45, or 49;

(iii) the complementarity determining regions of the VL amino acid sequence set forth in SEQ ID NOs. 7, 15, 19, 23, 27, 43, 47, or 51; or

(iv) a VL amino acid sequence that is at least 85% identical to the amino acid sequence set forth in SEQ ID NOs. 7, 15, 19, 23, 27, 43, 47, or 51.

11 .- 16 . (canceled)

17 . The antibody or antigen-binding fragment thereof of claim 9 , wherein

(i) the antibody or antigen-binding fragment thereof does not inhibit the association of fibrinogen with GPIIb/IIIa; or

(ii) the antibody or antigen-binding fragment thereof inhibits the association of fibrinogen with GPIIb/IIIa.

18 . (canceled)

19 . The antibody or antigen-binding fragment thereof of claim 17 , wherein the antibody or antigen-binding fragment thereof inhibits the association of fibrinogen with GPIIb/IIIa and comprises:

(i) the complementarity determining regions of the VH amino acid sequence set forth in: SEQ ID NOs. 13 or 17;

(ii) the VH amino acid sequence set forth in: SEQ ID NOs. 13 or 17;

(iii) the complementarity determining regions of the VL amino acid sequence set forth in: SEQ ID NOs. 15 or 19; or

(iv) the VL amino acid sequence set forth in: SEQ ID NOs. 15 or 19.

20 .- 22 . (canceled)

23 . An antibody or antigen-binding fragment thereof that specifically binds to Glycoprotein IIb/IIIa (GPIIb/IIIa), wherein the antibody or antigen-binding fragment thereof:

(a) specifically binds to GPIIb/IIIa at the same epitope as an antibody comprising the heavy chain variable domain (VH) and the light chain variable domain (VL) amino acid sequences set forth in:

(i) SEQ ID NOs. 5 and 7;

(ii) SEQ ID NOs. 9 and 11;

(iii) SEQ ID NOs. 13 and 15;

(iv) SEQ ID NOs. 17 and 19;

(v) SEQ ID NOs. 21 and 23;

(vi) SEQ ID NOs. 25 and 27;

(vii) SEQ ID NOs. 29 and 31;

(viii) SEQ ID NOs. 33 and 35;

(ix) SEQ ID NOs. 37 and 39;

(x) SEQ ID NOs. 41 and 43;

(xi) SEQ ID NOs. 45 and 47; or

(xii) SEQ ID NOs. 49 and 51; or

(b) competitively inhibits GPIIb/IIIa binding by an antibody comprising the heavy chain variable domain (VH) and the light chain variable domain (VL) amino acid sequences set forth in:

(i) SEQ ID NOs. 5 and 7;

(ii) SEQ ID NOs. 9 and 11;

(iii) SEQ ID NOs. 13 and 15;

(iv) SEQ ID NOs. 17 and 19;

(v) SEQ ID NOs. 21 and 23;

(vi) SEQ ID NOs. 25 and 27;

(vii) SEQ ID NOs. 29 and 31;

(viii) SEQ ID NOs. 33 and 35;

(ix) SEQ ID NOs. 37 and 39;

(x) SEQ ID NOs. 41 and 43;

(xi) SEQ ID NOs. 45 and 47; or

SEQ ID NOs. 49 and 51

(xii).

24 .- 25 . (canceled)

26 . An antibody or antigen-binding fragment thereof that specifically binds to Glycoprotein IIb/IIIa (GPIIb/IIIa), comprising a VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3, wherein

(i) the VH-CDR1 sequence comprises YTFTSYGIS (SEQ ID NO:53), the VH-CDR2 sequence comprises WISAYNGNTNYAQKLQG (SEQ ID NO:54), the VH-CDR3 sequence comprises ARDLEYYDSSGYAYGYFDL (SEQ ID NO:55), the VL-CDR1 sequence comprises RSSQSLLHSNGYNYLD (SEQ ID NO:83), the VL-CDR2 sequence comprises LGSNRAS (SEQ ID NO:84), and the VL-CDR3 sequence comprises MQALRLPRT (SEQ ID NO:85);

(ii) the VH-CDR1 sequence comprises GTFSSYAIS (SEQ ID NO:56), the VH-CDR2 sequence comprises GIIPIFGTANYAQKFQG (SEQ ID NO:57), the VH-CDR3 sequence comprises ARDTGYYGASLYFDY (SEQ ID NO:58), the VL-CDR1 sequence comprises RASQSVSSYLA (SEQ ID NO:86), the VL-CDR2 sequence comprises DASNRAT (SEQ ID NO:87), and the VL-CDR3 sequence comprises QQRSALPRT (SEQ ID NO:88);

(iii) the VH-CDR1 sequence comprises GTFSSYAIS (SEQ ID NO:56), the VH-CDR2 sequence comprises GIIPIFGTANYAQKFQG (SEQ ID NO:57), the VH-CDR3 sequence comprises ARGPPSAYGDYVWDI (SEQ ID NO:59), the VL-CDR1 sequence comprises RASQSVSSYLA (SEQ ID NO:86), the VL-CDR2 sequence comprises DSSNRAT (SEQ ID NO:89), and the VL-CDR3 sequence comprises QQRSHLPPT (SEQ ID NO:90);

(iv) the VH-CDR1 sequence comprises FTFSDHHMD (SEQ ID NO:60), the VH-CDR2 sequence comprises RTRNKANSYTTEYAASVKG (SEQ ID NO:61), the VH-CDR3 sequence comprises ARGPPYYADLGMGV (SEQ ID NO:62), the VL-CDR1 sequence comprises RASQSVSSNLA (SEQ ID NO:91), the VL-CDR2 sequence comprises GASTRAT (SEQ ID NO:92), and the VL-CDR3 sequence comprises QQFNLYPYT (SEQ ID NO:93);

(v) the VH-CDR1 sequence comprises YTFTSYSMH (SEQ ID NO:63), the VH-CDR2 sequence comprises IINPSGGSTSYAQKFQG (SEQ ID NO:64), the VH-CDR3 sequence comprises ARSYDIGYFDL (SEQ ID NO:65), the VL-CDR1 sequence comprises RASQSVSSYLA (SEQ ID NO:86), the VL-CDR2 sequence comprises DASKRAT (SEQ ID NO:94), and the VL-CDR3 sequence comprises QQDSFLPFT (SEQ ID NO:95);

(vi) the VH-CDR1 sequence comprises YTFTSYGIS (SEQ ID NO:53), the VH-CDR2 sequence comprises WISAYNGNTNYAQKLQG (SEQ ID NO:54), the VH-CDR3 sequence comprises ARGRPYDHYFDY (SEQ ID NO:66), the VL-CDR1 sequence comprises RASQSVSSYLA (SEQ ID NO:86), the VL-CDR2 sequence comprises DASNRAT (SEQ ID NO:87), and the VL-CDR3 sequence comprises QQAYNYPFT (SEQ ID NO:96);

(vii) the VH-CDR1 sequence comprises GSISSSSYYWG (SEQ ID NO:67), the VH-CDR2 sequence comprises SIYYSGSTYYNPSLKS (SEQ ID NO:68), the VH-CDR3 sequence comprises ARDFYSSVYGMDV (SEQ ID NO:69), the VL-CDR1 sequence comprises RASQSISSFLN (SEQ ID NO:97), the VL-CDR2 sequence comprises AASSLQS (SEQ ID NO:98), and the VL-CDR3 sequence comprises QQSYVHPLT (SEQ ID NO:99);

(viii) the VH-CDR1 sequence comprises YTFTSYGIS (SEQ ID NO:53), the VH-CDR2 sequence comprises WISAYNGNTNYAQKLQG (SEQ ID NO:54), the VH-CDR3 sequence comprises ARDGLGSSPWSAFDI (SEQ ID NO:70), the VL-CDR1 sequence comprises RSSQSLLHSNGYNYLD (SEQ ID NO: 100), the VL-CDR2 sequence comprises LGSNRAS (SEQ ID NO: 101), and the VL-CDR3 sequence comprises MQARRSPLT (SEQ ID NO:102);

(ix) the VH-CDR1 sequence comprises YTFTSYYMH (SEQ ID NO:71), the VH-CDR2 sequence comprises VINPSGGSTSYAQKFQG (SEQ ID NO:72), the VH-CDR3 sequence comprises ARLMSGSSGS (SEQ ID NO:73), the VL-CDR1 sequence comprises RASQSVSSSYLA (SEQ ID NO:103), the VL-CDR2 sequence comprises GASSRAT (SEQ ID NO: 104), and the VL-CDR3 sequence comprises QQYGGFPLT (SEQ ID NO: 105);

(x) the VH-CDR1 sequence comprises YTFTGYYMH (SEQ ID NO:74), the VH-CDR2 sequence comprises SINPNSGGTNYAQKFQG (SEQ ID NO:75), the VH-CDR3 sequence comprises ARDSSWKHDY (SEQ ID NO:76), the VL-CDR1 sequence comprises RASQSVSSYLA (SEQ ID NO:86), the VL-CDR2 sequence comprises DASNRAT (SEQ ID NO:87), and the VL-CDR3 sequence comprises QQYSFYPLT (SEQ ID NO: 106);

(xi) the VH-CDR1 sequence comprises YSISSGYYWG (SEQ ID NO:77), the VH-CDR2 sequence comprises SIYHSGSTNYNPSLKS (SEQ ID NO:78), the VH-CDR3 sequence comprises ARSPRWRSTYANWFNP (SEQ ID NO:79), the VL-CDR1 sequence comprises RASQGISSWLA (SEQ ID NO: 107), the VL-CDR2 sequence comprises GASSLQS (SEQ ID NO: 108), and the VL-CDR3 sequence comprises QQAAPFPLT (SEQ ID NO:109); or

(xii) the VH-CDR1 sequence comprises YSISSGYYWA (SEQ ID NO:80), the VH-CDR2 sequence comprises SIYHSGSTYYNPSLKS (SEQ ID NO:81), the VH-CDR3 sequence comprises AREHSSSGQWNV (SEQ ID NO: 82), the VL-CDR1 sequence comprises RASQSVSSYLA (SEQ ID NO:86), the VL-CDR2 sequence comprises DASNRAT (SEQ ID NO:87), and the VL-CDR3 sequence comprises QQRSFYFT (SEQ ID NO:110).

27 . An antibody or antigen-binding fragment thereof that specifically binds to Glycoprotein IIb/IIIa (GPIIb/IIIa), comprising a VH comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or 100% identical to any one of SEQ ID NOS: 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, or 49.

28 . An antibody or antigen-binding fragment thereof that specifically binds to Glycoprotein IIb/IIIa (GPIIb/IIIa), comprising a VL comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or 100% identical to any one of SEQ ID NOS: 7, 11, 15, 19, 23, 27, 31, 35, 39, 43, 47, or 51.

29 . The antibody or antigen-binding fragment thereof of claim 27 , comprising

(i) a VH comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or 100% identical to SEQ ID NO:5 and a VL comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or 100% identical to of SEQ ID NO:7;

(ii) a VH comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or 100% identical to SEQ ID NO:9 and a VL comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or 100% identical to SEQ ID NO: 11;

(iii) a VH comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or 100% identical to SEQ ID NO:13 and a VL comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or 100% identical to SEQ ID NO:15;

(iv) a VH comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or 100% identical to SEQ ID NO:17 and a VL comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or 100% identical to SEQ ID NO:19;

(v) a VH comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or 100% identical to SEQ ID NO:21 and a VL comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or 100% identical to SEQ ID NO:23;

(vi) a VH comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or 100% identical to SEQ ID NO:25 and a VL comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or 100% identical to SEQ ID NO:27;

(vii) a VH comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or 100% identical to SEQ ID NO:29 and a VL comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or 100% identical to SEQ ID NO:31;

(viii) a VH comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or 100% identical to SEQ ID NO:33 and a VL comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or 100% identical to SEQ ID NO:35;

(ix) a VH comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or 100% identical to SEQ ID NO:37 and a VL comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or 100% identical to SEQ ID NO:39;

(x) a VH comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or 100% identical to SEQ ID NO:41 and a VL comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or 100% identical to SEQ ID NOS:43;

(xi) a VH comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or 100% identical to SEQ ID NO:45 and a VL comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or 100% identical to SEQ ID NO:47; or

(xii) a VH comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or 100% identical to SEQ ID NO:49 and a VL comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or 100% identical to SEQ ID NO:51.

30 . The antibody or antigen-binding fragment thereof of claim 29 , wherein the antibody or antigen-binding fragment thereof comprises a VH and a VL comprising the amino acid sequence set forth in:

(i) SEQ ID NOs. 5 and 7;

(ii) SEQ ID NOs. 9 and 11;

(iii) SEQ ID NOs. 13 and 15;

(iv) SEQ ID NOs. 17 and 19;

(v) SEQ ID NOs. 21 and 23;

(vi) SEQ ID NOs. 25 and 27;

(vii) SEQ ID NOs. 29 and 31;

(viii) SEQ ID NOs. 33 and 35;

(ix) SEQ ID NOs. 37 and 39;

(x) SEQ ID NOs. 41 and 43;

(xi) SEQ ID NOs. 45 and 47; or

(xii) SEQ ID NOs. 49 and 51.

31 . The antibody or antigen binding fragment thereof of claim 27 , comprising a VH-CDR1, VH-CDR2, and VH-CDR3, wherein

(i) the VH-CDR1 sequence comprises YTFTSYGIS (SEQ ID NO:53), the VH-CDR2 sequence comprises WISAYNGNTNYAQKLQG (SEQ ID NO:54), and the VH-CDR3 sequence comprises ARDLEYYDSSGYAYGYFDL (SEQ ID NO:55);

(ii) the VH-CDR1 sequence comprises GTFSSYAIS (SEQ ID NO:56), the VH-CDR2 sequence comprises GIIPIFGTANYAQKFQG (SEQ ID NO:57), and the VH-CDR3 sequence comprises ARDTGYYGASLYFDY (SEQ ID NO:58);

(iii) the VH-CDR1 sequence comprises GTFSSYAIS (SEQ ID NO:56), the VH-CDR2 sequence comprises GIIPIFGTANYAQKFQG (SEQ ID NO:57), and the VH-CDR3 sequence comprises ARGPPSAYGDYVWDI (SEQ ID NO:59);

(iv) the VH-CDR1 sequence comprises FTFSDHHMD (SEQ ID NO:60), the VH-CDR2 sequence comprises RTRNKANSYTTEYAASVKG (SEQ ID NO:61), and the VH-CDR3 sequence comprises ARGPPYYADLGMGV (SEQ ID NO:62);

(v) the VH-CDR1 sequence comprises YTFTSYSMH (SEQ ID NO:63), the VH-CDR2 sequence comprises IINPSGGSTSYAQKFQG (SEQ ID NO:64), and the VH-CDR3 sequence comprises ARSYDIGYFDL (SEQ ID NO:65);

(vi) the VH-CDR1 sequence comprises YTFTSYGIS (SEQ ID NO:53), the VH-CDR2 sequence comprises WISAYNGNTNYAQKLQG (SEQ ID NO:54), and the VH-CDR3 sequence comprises ARGRPYDHYFDY (SEQ ID NO:66);

(vii) the VH-CDR1 sequence comprises GSISSSSYYWG (SEQ ID NO:67), the VH-CDR2 sequence comprises SIYYSGSTYYNPSLKS (SEQ ID NO:68), and the VH-CDR3 sequence comprises ARDFYSSVYGMDV (SEQ ID NO:69);

(viii) the VH-CDR1 sequence comprises YTFTSYGIS (SEQ ID NO:53), the VH-CDR2 sequence comprises WISAYNGNTNYAQKLQG (SEQ ID NO:54), and the VH-CDR3 sequence comprises ARDGLGSSPWSAFDI (SEQ ID NO:70);

(ix) the VH-CDR1 sequence comprises YTFTSYYMH (SEQ ID NO:71), the VH-CDR2 sequence comprises VINPSGGSTSYAQKFQG (SEQ ID NO:72), and the VH-CDR3 sequence comprises ARLMSGSSGS (SEQ ID NO:73);

(x) the VH-CDR1 sequence comprises YTFTGYYMH (SEQ ID NO:74), the VH-CDR2 sequence comprises SINPNSGGTNYAQKFQG (SEQ ID NO:75), and the VH-CDR3 sequence comprises ARDSSWKHDY (SEQ ID NO:76);

(xi) the VH-CDR1 sequence comprises YSISSGYYWG (SEQ ID NO:77), the VH-CDR2 sequence comprises SIYHSGSTNYNPSLKS (SEQ ID NO:78), and the VH-CDR3 sequence comprises ARSPRWRSTYANWFNP (SEQ ID NO:79); or

(xii) the VH-CDR1 sequence comprises YSISSGYYWA (SEQ ID NO:80), the VH-CDR2 sequence comprises SIYHSGSTYYNPSLKS (SEQ ID NO:81), and the VH-CDR3 sequence comprises AREHSSSGQWNV (SEQ ID NO: 82).

32 . The antibody or antigen binding fragment thereof of claim 28 , comprising a VL-CDR1, VL-CDR2, and VL-CDR3, wherein

(i) the VL-CDR1 sequence comprises RSSQSLLHSNGYNYLD (SEQ ID NO:83), the VL-CDR2 sequence comprises LGSNRAS (SEQ ID NO:84), and the VL-CDR3 sequence comprises MQALRLPRT (SEQ ID NO:85);

(ii) the VL-CDR1 sequence comprises RASQSVSSYLA (SEQ ID NO:86), the VL-CDR2 sequence comprises DASNRAT (SEQ ID NO:87), and the VL-CDR3 sequence comprises QQRSALPRT (SEQ ID NO:88);

(iii) the VL-CDR1 sequence comprises RASQSVSSYLA (SEQ ID NO:86), the VL-CDR2 sequence comprises DSSNRAT (SEQ ID NO:89), and the VL-CDR3 sequence comprises QQRSHLPPT (SEQ ID NO:90);

(iv) the VL-CDR1 sequence comprises RASQSVSSNLA (SEQ ID NO:91), the VL-CDR2 sequence comprises GASTRAT (SEQ ID NO:92), and the VL-CDR3 sequence comprises QQFNLYPYT (SEQ ID NO:93);

(v) the VL-CDR1 sequence comprises RASQSVSSYLA (SEQ ID NO:86), the VL-CDR2 sequence comprises DASKRAT (SEQ ID NO:94), and the VL-CDR3 sequence comprises QQDSFLPFT (SEQ ID NO:95);

(vi) the VL-CDR1 sequence comprises RASQSVSSYLA (SEQ ID NO:86), the VL-CDR2 sequence comprises DASNRAT (SEQ ID NO:87), and the VL-CDR3 sequence comprises QQAYNYPFT (SEQ ID NO:96);

(vii) the VL-CDR1 sequence comprises RASQSISSFLN (SEQ ID NO:97), the VL-CDR2 sequence comprises AASSLQS (SEQ ID NO:98), and the VL-CDR3 sequence comprises QQSYVHPLT (SEQ ID NO:99);

(viii) the VL-CDR1 sequence comprises RSSQSLLHSNGYNYLD (SEQ ID NO: 100), the VL-CDR2 sequence comprises LGSNRAS (SEQ ID NO: 101), and the VL-CDR3 sequence comprises MQARRSPLT (SEQ ID NO: 102);

(ix) the VL-CDR1 sequence comprises RASQSVSSSYLA (SEQ ID NO: 103), the VL-CDR2 sequence comprises GASSRAT (SEQ ID NO: 104), and the VL-CDR3 sequence comprises QQYGGFPLT (SEQ ID NO: 105);

(x) the VL-CDR1 sequence comprises RASQSVSSYLA (SEQ ID NO:86), the VL-CDR2 sequence comprises DASNRAT (SEQ ID NO:87), and the VL-CDR3 sequence comprises QQYSFYPLT (SEQ ID NO: 106);

(xi) the VL-CDR1 sequence comprises RASQGISSWLA (SEQ ID NO: 107), the VL-CDR2 sequence comprises GASSLQS (SEQ ID NO: 108), and the VL-CDR3 sequence comprises QQAAPFPLT (SEQ ID NO:109); or

(xii) the VL-CDR1 sequence comprises RASQSVSSYLA (SEQ ID NO:86), the VL-CDR2 sequence comprises DASNRAT (SEQ ID NO:87), and the VL-CDR3 sequence comprises QQRSFYFT (SEQ ID NO: 110).

33 . The antibody or antigen binding fragment thereof of claim 26 , wherein the antibody or antigen binding fragment thereof is a whole antibody, a Fab, a Fab′, a F(ab)2, an scFv, an sc(Fv)2, or a diabody.

34 . A chimeric molecule comprising (i) the antibody or antigen-binding fragment thereof of claim 26 , and (ii) a heterologous moiety.

35 . The chimeric molecule of claim 34 , wherein the heterologous moiety comprises a clotting factor.

36 .- 42 . (canceled)

43 . The chimeric molecule of claim 34 , further comprising a second heterologous moiety.

44 . The chimeric molecule according to claim 43 , wherein the second heterologous moiety comprises a half-life extending moiety.

45 .- 46 . (canceled)

47 . A chimeric molecule comprising (i) the antibody or antigen-binding fragment thereof of claim 26 , (ii) a recombinant Factor VIIa comprising a heavy chain and a light chain, and (iii) a half-life extending moiety.

48 . The chimeric molecule of claim 47 , wherein the antibody or antigen-binding fragment thereof is an Fab or an scFv.

49 . The chimeric molecule of claim 47 , wherein the heavy chain of the recombinant Factor VIIa is linked to the half-life extending moiety and the half-life extending moiety is linked to the antibody or antigen-binding fragment thereof.

50 . The chimeric molecule of claim 49 , wherein the recombinant Factor VIIa is linked to the half-life extending moiety via a first peptide linker and the half-life extending moiety is linked to the antibody or antigen-binding fragment thereof via a second peptide linker.

51 . The chimeric molecule of claim 50 , wherein the heavy chain of the recombinant Factor VIIa is linked to the half-life extending moiety via a first peptide linker and the half-life extending moiety is linked to the light chain of the antibody or antigen-binding fragment thereof via a second peptide linker.

52 . (canceled)

53 . A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof of claim 26 , and a pharmaceutically acceptable carrier.

54 . A method of reducing the frequency or degree of a bleeding episode in a human subject in need thereof, comprising administering to the subject an effective amount of the antibody or antigen-binding fragment thereof claim 26 .

55 . The method of claim 54 , wherein the subject has developed or has a tendency to develop an inhibitor against Factor VIII (“FVIII”), Factor IX (“FIX”), or both.

56 . The method of claim 55 , wherein the inhibitor against FVIII or FIX is a neutralizing antibody against FVIII, FIX, or both.

57 . The method of claim 54 , wherein the bleeding episode is the result of hemarthrosis, muscle bleed, oral bleed, hemorrhage, hemorrhage into muscles, oral hemorrhage, trauma, trauma capitis, gastrointestinal bleeding, intracranial hemorrhage, intra-abdominal hemorrhage, intrathoracic hemorrhage, bone fracture, central nervous system bleeding, bleeding in the retropharyngeal space, bleeding in the retroperitoneal space, bleeding in the illiopsoas sheath, or any combinations thereof.

58 . A method of treating a blood coagulation disorder in a human subject in need thereof, comprising administering to the subject an effective amount of the antibody or antigen-binding fragment thereof of claim 26 .

59 . The method of claim 58 , wherein the blood coagulation disorder is hemophilia A or hemophilia B.

60 . (canceled)

61 . A method of detecting platelets, comprising:

contacting a human blood preparation with the antibody or antigen-binding fragment thereof of claim 26 ; and

detecting cells in the blood preparation to which the antibody or antigen-binding fragment thereof binds.

62 . A method for enriching platelets, comprising:

contacting a human blood preparation with the antibody or antigen-binding fragment thereof of claim 26 ; and

enriching cells to which the antibody or antigen-binding fragment thereof are bound as compared to those cells in the blood preparation that are not bound by the antibody or antigen-binding fragment thereof.

63 . An isolated nucleic acid comprising a nucleotide sequence that is at least 80% identical to a nucleotide sequence selected from the group consisting of SEQ ID NOs: 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, and 52.

64 . (canceled)

65 . An isolated nucleic acid comprising a nucleotide sequence that encodes a polypeptide comprising an amino acid sequence that is at least 75% identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, and 51.

66 . (canceled)

67 . An isolated protein encoded by the nucleic acid of claim 63 .

68 . A recombinant vector comprising the nucleic acid of claim 63 .

69 . A host cell comprising the recombinant vector of claim 68 .

70 . A method of preparing an antibody or antigen-binding fragment thereof, the method comprising culturing a host cell comprising recombinant vectors comprising:

the nucleic acid sequences set forth in SEQ ID NOs: 6 and 8;

the nucleic acid sequences set forth in SEQ ID NOs: 10 and 12;

the nucleic acid sequences set forth in SEQ ID NOs: 14 and 16;

the nucleic acid sequences set forth in SEQ ID NOs: 18 and 20;

the nucleic acid sequences set forth in SEQ ID NOs: 22 and 24;

the nucleic acid sequences set forth in SEQ ID NOs: 26 and 32;

the nucleic acid sequences set forth in SEQ ID NOs: 34 and 36;

the nucleic acid sequences set forth in SEQ ID NOs: 38 and 40;

the nucleic acid sequences set forth in SEQ ID NOs: 42 and 44;

the nucleic acid sequences set forth in SEQ ID NOs: 46 and 48; or

the nucleic acid sequences set forth in SEQ ID NOs: 50 and 52,

under conditions appropriate for expression and production of the antibody or antigen-binding fragment thereof.

71 . The method of claim 70 , further comprising isolating the antibody or antigen-binding fragment thereof.

72 . (canceled)